Biotech Values

[biomaven0]

I did ask my nephew about this (he's an oncology fellow at Hopkins focusing on prostate), and he said there is often significant fatigue with enzalutamide which might well be an issue dissuading earlier use. Unclear if the Aragon compound will have similar issues or not. He viewed these two drugs as likely the last word on the androgen receptor side - going to need a different approach to make a significant advance.

FWIW, he said he is now positive on PSA screening - the increasing adoption of "watchful waiting" gives screening a better risk/reward than it used to have.

Peter